Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study

This study was registered at www.clinicaltrials.gov as identifier NCT01135641.

Source: Blood - November 16, 2017 Category: Hematology Authors: Malard, F., Labopin, M., Yakoub-Agha, I., Chantepie, S., Guillaume, T., Blaise, D., Tabrizi, R., Magro, L., Vanhove, B., Blancho, G., Moreau, P., Gaugler, B., Chevallier, P., Mohty, M. Tags: Transplantation, Free Research Articles, Clinical Trials and Observations Source Type: research